Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation

Blood

Volumn 107, Issue 6, 2006, Pages 2294-2302

  Berger, Carolina ^a   Flowers, Mary E ^b   Warren, Edus H ^b   Riddell, Stanley R ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; CYTOKINE; EPITOPE; HERPES SIMPLEX VIRUS THYMIDINE KINASE; IMATINIB; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; T LYMPHOCYTE ANTIBODY; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADOPTIVE TRANSFER; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL BASED GENE THERAPY; CELL TRANSFER; CHILL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA MODIFICATION; FEVER; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MEMORY CELL; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; PRIORITY JOURNAL; RECIPIENT; SUICIDE GENE; SUICIDE GENE THERAPY; T LYMPHOCYTE; TRANSGENE;

EID: 33644750264     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-08-3503     Document Type: Article

References (56)

1. Yee C, Thompson JA, Roche P, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med. 2000;192:1637-1643.
2. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
3. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
4. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev. 1997;157:125-140.
5. Kolb H-J, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103:767-776.
6. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukemia effect. Nat Rev Cancer. 2004;4:371-380.
7. Liu K, Rosenberg SA. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol. 2001;167:6356-6365.
8. Lal S, Lauer UM, Niethammer D, Beck JF, Schlegel PG. Suicide genes: past, present and future perspectives. Immunol Today. 2000;21:48-54.
9. Spencer DM. Developments in suicide genes for preclinical and clinical applications. Curr Opin Mol Ther. 2000;2:433-440.
10. Heyman RA, Borrelli E, Lesley J, et al. Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. Proc Natl Acad Sci U S A. 1989;86:2698-2702.
11. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med. 1996;2:216-223.
12. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719-1724.
13. Verzeletti S, Bonini C, Marktel S, et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther. 1998;9:2243-2251.
14. Tiberghien P, Ferrand C, Lioure B, et al. Administration of herplex simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 2001;97:63-72.
15. + enriched blood stem cells. Blood. 2004;140:3408-3409.
16. Burt RK, Drobyski WR, Seregina T, et al. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp Hematol. 2003;31:903-910.
17. Sauce D, Bodinier M, Garin M, et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood. 2002;99:1165-1173.
18. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
19. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304.
20. Lupton SD, Brunton LL, Kalberg VA, Overall RA. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol Cell Biol. 1991;11:3374-3378.
21. Marini FC III, Kornblau SM. Production and culture of HSVtk-transduced suicidal lymphocytes induces variable changes in the lymphocyte subset composition. Bone Marrow Transplant. 1999;23:907-915.
22. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods. 1990;128:189-201.
23. Miller AD, Bonham L, Alfano J, et al. A novel murine retrovirus identified during testing for helper virus in human gene transfer trials. J Virol. 1996;70:1804-1809.
24. Berger C, Huang M-L, Gough M, et al. Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous T cells in a nonhuman primate model. J Virol. 2001;75:799-808.
25. Higano CS, Chielens D, Raskind W, et al. Use of α-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood. 1997;90:2549-2554.
26. Higano CS, Raskind WH, Singer JW. Use of α interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood. 1992;80:1437-1442.
27. Kolb H-J, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041-2050.
28. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
29. Flowers MED, Leisenring W, Beach K, et al. Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leucocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. Biol Blood Marrow Transplant. 2000;6:321-326.
30. Porter DL, Collins RH Jr, Hardy C, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood. 2000;95:1214-1221.
31. Bonini C, Grez M, Traversari C, et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med. 2003;9:367-369.
32. Introna M, Barbui AM, Bambacioni F, et al. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther. 2000;11:611-620.
33. Rettig MP, Ritchey JK, Meyerrose TE, Haug JS, Dipersio JF. Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease. Mol Ther. 2003;8:29-41.
34. Fehse B, Richters A, Putimtseva-Scharf K, et al. CD34 splice variants: an attractive marker for selection of gene-modified cells. Mol Ther. 2000;1:448-456.
35. Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 1994;54:1503-1506.
36. Ferrand C, Robinet E, Contassot E, et al. Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor β chain hypervariable region repertoire. Hum Gene Ther. 2000;11:1151-1164.
37. Kornblau SM, Stiouf I, Snell V, et al. Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Cancer Res. 2001;61:3355-3360.
38. Marktel S, Magnani Z, Ciceri F, et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood. 2003;101:1290-1298.
39. Berger C, Blau CA, Clackson T, Riddell SR, Heimfeld S. CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy. Blood. 2003;101:476-484.
40. Robinet E, Fehse B, Ebeling S, et al. Improving the ex vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune function. Cytotherapy. 2005;7:150-157.
41. Cavalieri S, Cazzaniga S, Geuna M, et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR-activation maintain an intact immune competence. Blood. 2003;102:497-505.
42. + cytotoxic T lymphocytes. J Virol. 2000;74:4465-4473.
43. Maecker HT, Dunn HS, Suni MA, et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods. 2001;255:27-40.
44. Maecker HT, Maino VC. Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry. Hum Immunol. 2004;65:493-499.
45. Shimizu Y, DeMars R. Demonstration by class I gene transfer that reduced susceptibility of human cells to natural killer cell-mediated lysis is inversely correlated with HLA class I antigen expression. Eur J Immunol. 1989;19:447-451.
46. + hematopoietic cells. Blood. 2001;97:1951-1959.
47. MacCorkle RA, Freeman KW, Spencer DM. Synthetic activation of caspases: artificial death switches. Proc Natl Acad Sci U S A. 1998;95:3655-3660.
48. Thomis DC, Marktel S, Bonini C, et al. A Fasbased suicide switch in human T cells for the treatment of graft-versus-host disease. Blood. 2001;97:1249-1257.
49. Berger C, Blau CA, Huang ML, et al. Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood. 2004;103:1261-1269.
50. Straathof KC, Pulè MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105:4247-4254.
51. Fan L, Freeman KW, Khan T, Pham E, Spencer DM. Improved artificial death switches based on caspases and FADD. Hum Gene Ther. 1999;10:2273-2285.
52. Nör JE, Hu Y, Song W, Spencer DM, Núñez G. Ablation of microvessels in vivo upon dimerization of iCaspase-9. Gene Ther. 2002;9:444-451.
53. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190-195.
54. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388:300-304.
55. Boise LH, Gottschalk AR, Quintáns J, Thompson CB. Bcl-2 and Bcl-2-related proteins in apoptosis regulation. Curr Top Microbiol Immunol. 1995;200:107-121.
56. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.